News

BNT327, BioNTech’s PD-L1xVEGF-A bispecific antibody, is a clinically advanced investigational immunotherapy candidate with the potential to surpass current checkpoint inhibitor outcomes and set ...
Bristol Myers Squibb (NYSE:BMY) is paying up to $11.1B in a licensing agreement to help develop BioNTech's (NASDAQ:BNTX) immunotherapy bispecific antibody BNT327 for solid tumors. The candidate ...
Bristol Myers Squibb BMY announced a strategic collaboration agreement with BioNTech BNTX for the global co-development and ...
Doctors are exploring whether adding BNT327 to standard chemotherapy will help it to work better. But they don’t know this for sure, so they want to find this out. First, they need to find the best ...
Acquisition to strengthen key pillar of BioNTech’s oncology strategy aimed at establishing BNT327 as a pan-tumor technology platform for the treatment of advanced cancersWith the closing of the ...
This trial is comparing BNT327 and standard chemotherapy with atezolizumab and standard chemotherapy. It is for people having their first treatment for small cell lung cancer that has spread within ...
BioNTech's acquisition of Biotheus includes $800M upfront and up to $150M in milestone payments. The deal grants BioNTech full rights to late-stage bispecific antibody BNT327/PM8002. From tariffs ...
BioNTech SE (BNTX, Financials) announced plans to acquire Biotheus, a clinical-stage biotechnology company, for $800 million, securing full global rights to BNT327/PM8002, an investigational ...
BNT327, BioNTech’s PD-L1xVEGF-A bispecific antibody, is a clinically advanced investigational immunotherapy candidate with the potential to surpass current checkpoint inhibitor outcomes and set ...
BioNTech’s BNT327, a next-generation bispecific antibody candidate targeting PD-L1 and VEGF-A, is currently being evaluated in multiple ongoing trials with more than 1,000 patients treated to ...
BNT327, BioNTech’ s PD-L1xVEGF-A bispecific antibody, is a clinically advanced investigational immunotherapy candidate with the potential to surpass current checkpoint inhibitor outcomes and set ...